Carmen Burtea

Prof. Carmen Burtea

University of Mons
orcid

Research Focus & Metrics

Academic Career Length

36Years (1991-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
10 January 2012 in PLOS ONE
Verified
Journal Article
Open access
PDF file
SLSophie Laurent
Sophie Laurent
Carmen BurteaCarmen Burtea
Carmen Burtea
CTCoralie Thirifays
Coralie Thirifays
UHUrs Hafeli
Urs Hafeli
Morteza MahmoudiMorteza Mahmoudi
Morteza Mahmoudi
Until now, the results of nanotoxicology research have shown that the interactions between nanoparticles (NPs) and cells are remarkably complex. In order to get a deep understanding of the NP-cell interactions, scientists have focused on the physicochemical effects. However, there are still considerable debates about the regulation of nanomaterials and the reported results are usually in contradictions. Here, we are going to introduce the potential key reasons for these conflicts. In this case, modification of conventional in vitro toxicity assays, is one of the crucial ignored matter in nanotoxicological sciences. More specifically, the conventional methods neglect important factors such as the sedimentation of NPs and absorption of proteins and other essential biomolecules onto the surface of NPs. Another ignored matter in nanotoxicological sciences is the effect of cell “vision” (i.e., cell type). In order to show the effects of these ignored subjects, we probed the effect of superparamagnetic iron oxide NPs (SPIONs), with various surface chemistries, on various cell lines. We found thatthe modification of conventional toxicity assays and the consideration of the “cell vision” concept are crucial matters to obtain reliable, and reproducible nanotoxicology data. These new concepts offer a suitable way to obtain a deep understanding on the cell-NP interactions. In addition, by consideration of these ignored factors, the conflict of future toxicological reports would be significantly decreased.

22 June 2012 in Nanoscale
Verified
Journal Article
Closed access
PDF file
Morteza MahmoudiMorteza Mahmoudi
Morteza Mahmoudi
SSSeyyed N. Saeedi-Eslami
Seyyed N. Saeedi-Eslami
MSMohammad ali Shokrgozar
Mohammad ali Shokrgozar
KAKayhan Azadmanesh
Kayhan Azadmanesh
MHMaryam Hassanlou
Maryam Hassanlou
HVHojatollah Vali
Hojatollah Vali
Engineered nanoparticles are increasingly being considered for use as biosensors, imaging agents and drug delivery vehicles. Their versatility in design and applications make them an attractive proposition for new biological and biomedical approaches. Despite the remarkable speed of development in nanoscience, relatively little is known about the interaction of nanoscale objects with living systems. In a biological fluid, proteins associate with nanoparticles, and the amount and the presentation of the proteins on their surface could lead to a different in vivo response than an uncoated particle. Here, in addition to protein adsorption, we are going to introduce concept of cell “vision”, which would be recognized as another crucial factor that should be considered for the safe design of any type of nanoparticles that will be used in specific biomedical applications. The impact of exactly the same nanoparticles on various cells is significantly different and could not be assumed for other cells; the possible mechanisms that justify this cellular response relate to the numerous detoxification strategies that any particular cell can utilize in response to nanoparticles. The uptake and defence mechanism could be considerably different according to the cell type. Thus, what the cell “sees”, when it is faced with nanoparticles, is most likely dependent on the cell type.

1 January 2008
Verified
Book Chapter
Closed access
PDF file
Carmen BurteaCarmen Burtea
Carmen Burtea
SLSophie Laurent
Sophie Laurent
LELuce Vander Elst
Luce Vander Elst
RMRobert N. Muller
Robert N. Muller

3 January 2008 in Cardiovascular Research
Verified
Journal Article
Open access
PDF file
Carmen BurteaCarmen Burtea
Carmen Burtea
SLSophie Laurent
Sophie Laurent
OMOltea Murariu
Oltea Murariu
DRDirk Rattat
Dirk Rattat
GTGérard Toubeau
Gérard Toubeau
RMRobert N. Muller
Robert N. Muller
The integrin αvβ3 is highly expressed in atherosclerotic plaques by medial and intimal smooth muscle cells and by endothelial cells of angiogenic microvessels. In this study, we have assessed non-invasive molecular magnetic resonance imaging (MRI) of plaque-associated αvβ3 integrin expression on transgenic ApoE−/− mice with a low molecular weight peptidomimetic of Arg-Gly-Asp (mimRGD) grafted to gadolinium diethylenetriaminepentaacetate (Gd-DTPA-g-mimRGD). The analogous compound Eu-DTPA-g-mimRGD was employed for an in vivo competition experiment and to confirm the molecular targeting. The specific interaction of mimRGD conjugated to Gd-DTPA or to 99mTc-DTPA with αvβ3 integrin was furthermore confirmed on Jurkat T lymphocytes. The mimRGD was synthesized and conjugated to DTPA. DTPA-g-mimRGD was complexed with GdCl3·6H2O, EuCl3·6H2O, or with [99mTc(CO)3(H2O)3]+. MRI evaluation was performed on a 4.7 T Bruker imaging system. Blood pharmacokinetics of Gd-DTPA-g-mimRGD were assessed in Wistar rats and in c57bl/6j mice. The presence of angiogenic blood vessels and the expression of αvβ3 integrin were confirmed in aorta specimens by immunohistochemistry. Gd-DTPA-g-mimRGD produced a strong enhancement of the external structures of the aortic wall and of the more profound layers (possibly tunica media and intima). The aortic lumen seemed to be restrained and distorted. Pre-injection of Eu-DTPA-g-mimRGD diminished the Gd-DTPA-g-mimRGD binding to atherosclerotic plaque and confirmed the specific molecular targeting. A slower blood clearance was observed for Gd-DTPA-g-mimRGD, as indicated by a prolonged elimination half-life and a diminished total clearance. The new compound is potentially useful for the diagnosis of vulnerable atherosclerotic plaques and of other pathologies characterized by αvβ3 integrin expression, such as cancer and inflammation. The delayed blood clearance, the significant enhancement of the signal-to-noise ratio, and the low immunogenicity of the mimetic molecule highlight its potential for an industrial and clinical implementation.

10 September 2009 in Molecular Pharmaceutics
Verified
Journal Article
Closed access
Carmen BurteaCarmen Burtea
Carmen Burtea
SLSophie Laurent
Sophie Laurent
ELEric Lancelot
Eric Lancelot
SBSébastien Ballet
Sébastien Ballet
OMOltea Murariu
Oltea Murariu
RMRobert N. Muller
Robert N. Muller

1 November 2009 in Contrast Media & Molecular Imaging
Verified
Journal Article
Closed access
PDF file
SBSébastien Boutry
Sébastien Boutry
DFDelphine Forge
Delphine Forge
Carmen BurteaCarmen Burtea
Carmen Burtea
IMIsabelle Mahieu
Isabelle Mahieu
OMOltea Murariu
Oltea Murariu
RMRobert N. Muller
Robert N. Muller